DBV Technologies SA – (NASDAQ:DBVT) was the target of some unusual options trading on Tuesday. Stock traders purchased 354 put options on the company. This is an increase of 608% compared to the typical volume of 50 put options.

Institutional investors have recently added to or reduced their stakes in the stock. OLD Mission Capital LLC raised its holdings in DBV Technologies by 498.5% during the 4th quarter. OLD Mission Capital LLC now owns 50,875 shares of the company’s stock worth $1,252,000 after purchasing an additional 42,374 shares during the last quarter. Perceptive Advisors LLC raised its holdings in DBV Technologies by 3,604.2% during the 4th quarter. Perceptive Advisors LLC now owns 978,619 shares of the company’s stock worth $24,075,000 after purchasing an additional 952,200 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in DBV Technologies by 94.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,007,684 shares of the company’s stock worth $49,389,000 after purchasing an additional 977,491 shares during the last quarter. University of Notre Dame DU Lac raised its holdings in DBV Technologies by 94.3% during the 4th quarter. University of Notre Dame DU Lac now owns 115,115 shares of the company’s stock worth $2,832,000 after purchasing an additional 55,860 shares during the last quarter. Finally, Sectoral Asset Management Inc raised its holdings in DBV Technologies by 14.2% during the 4th quarter. Sectoral Asset Management Inc now owns 60,298 shares of the company’s stock worth $1,483,000 after purchasing an additional 7,499 shares during the last quarter. 46.36% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on the company. BidaskClub cut DBV Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 6th. Societe Generale cut DBV Technologies from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Zacks Investment Research raised DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Tuesday, October 24th. JMP Securities assumed coverage on DBV Technologies in a report on Friday, November 17th. They issued an “outperform” rating for the company. Finally, Barclays cut their price target on DBV Technologies from $58.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $49.63.

DBV Technologies (NASDAQ DBVT) opened at $26.23 on Thursday. DBV Technologies has a twelve month low of $20.08 and a twelve month high of $50.57.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/02/15/dbv-technologies-sees-unusually-large-options-volume-dbvt-2.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.